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In speaking of enhanced autonomy, we intended to con-
vey that today’s patients can independently access medical in-
formation and a growing array of products and services, free
from physician gatekeeping, that they could not in the past.
This modest claim seems indisputable. After all, any inter-
ested adult can perform a do-it-yourself electrocardiogram or
order a genetic test that screens for 3 specific BRCA1 and BRCA2
mutations. Until recently, these tests were available only
through a health care professional and were typically limited
to patients with a medical indication.
Weinlander appropriately asks whether this new state of
affairs is normatively preferable to the previous status quo.
Perhaps being able to independently access medical in-
formation and take medical actions does not enhance,
in the sense of improve, patient autonomy. We agree that
physicians must help their patients interpret and under-
stand complex medical information, whether from online
sources or direct-to-consumer tests. We also agree that
patients’ access to information and direct-to-consumer
products and services can lead to confusion and uncertainty
and that physicians should be prepared to help patients
interpret findings and pursue appropriate medical manage-
ment options. Like Weinlander, we agree that physicians
should inquire further before referring or ordering addi-
tional tests and screenings. Moreover, physicians should
help patients appreciate why additional services are or are
not needed, thereby promoting health literacy. In sum, we
share Weinlander’s view that physicians should not act as
mere advisers and gatekeepers but should rather leverage
their experience and knowledge to help patients use the
available information and resources in ways that benefit
them and cohere with their values and goals. The role of
physicians may be changing, but it remains both challenging
and ethically rich.
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Additional Approaches to Treatment
of Depression
To the Editor Dr Cuijpers provided a succinct summary of the
many challenges faced by clinicians in the treatment and
management of depression.1 Although depression is one of
the most common psychiatric disorders, it is also one the
most challenging to treat. I concur with Cuijpers’ recom-
mendations for management strategies that optimize what
is already known about depression and its treatment and
the need for further research on the causes of depression to
guide the development of more effective treatments. How-
ever, another approach to achieving better treatment out-
comes begins with the recognition that some symptoms
tend to respond well to most established depression treat-
ments but some do not.
Fatigue, loss of energy, and sleep disturbances are among
the most common symptoms of depression before treat-
ment and among the most common residual symptoms
after treatment, even among patients who meet standard cri-
teria for remission.2 For example, in a primary care study,
fatigue or loss of energy was reported by 90% and sleep prob-
lems by 85% of the depressed patients prior to treatment,
and by 35% and 39%, respectively, of patients who no longer
met criteria for a major depressive episode after treatment. In
contrast, only 21% continued to report the core depression
symptoms.3 Thus, standard treatments for depression may
not be as effective for fatigue, loss of energy, and disturbed
sleep as they are for most other symptoms of depression.
This is especially concerning because these symptoms are
also among the best predictors of relapse and recurrent
depressive episodes.4
Thus, for many patients, the achievement of sustained
remission depends on finding better ways to treat these
residual symptoms. Promising candidates for augmentation
of traditional depression treatments include tailored exer-
cise training, cognitive behavioral therapy for disordered
sleep, and melatonin agonists, to name a few. A meta-
analysis of studies of cognitive behavioral therapy for
insomnia in depressed patients, for example, showed a
3-fold higher likelihood of depression remission compared
with control conditions.5 In current clinical practice,
residual symptoms are rarely targeted after the initial treat-
ment of major depression. Research directed toward identi-
fying interventions that improve these symptoms, either
concurrent with or following traditional depression treat-
ments, may greatly improve treatment outcomes while a
deeper understanding of the causes of depression and the
novel treatments that may follow are sought.
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To the Editor In a Viewpoint article, Dr Cuijpers1 suggested
that the priority for improving treatments for depression
should be on identifying which patients will respond so that
better treatments can be developed. We agree with this call
for personalized and precision medicine for depression.
However, the author adopted a traditional latent disease
model of depression, which is unlikely to accomplish this
goal. More specifically, we identify a number of limitations
in Cuijpers’ arguments.
First, depression is a highly heterogeneous disorder. Based
on self-report data, the diagnosis has been assigned to indi-
viduals with widely differing sets of problems that are as-
sumed to be the independent expressions of 1 or more latent
disease entities. This simplistic medical model has led to the
disappointing results summarized in the Viewpoint. More re-
cently, complex network approaches offer an alternative and
less restrictive model,2 with depression being viewed as a set
of functionally interconnected problems leading to psychic
pain. This approach opens new opportunities for treatment,
psychopathology, and nosology.
Second, the identification of processes suggested by the
author does not necessitate the development of new treat-
ments. Modern conceptions of empirically supported inter-
ventions, such as cognitive behavioral therapy, include a high
degree of precision in targeting etiological processes.3 Ex-
amples of treatment processes include attentional retraining,
emotion regulation, and interpersonal skill training. A pro-
cess focus is thus a feature of present-day treatments.
Third, the author mainly based his conclusions on random-
ized clinical trials that implied the existence of a latent disease
entity and did not consider the significant body of literature ex-
amining the manner of intervention delivery, known as in-
session processes or mediators of outcome. An element of the
patient-clinician relationship, the working alliance, shows ro-
bust significant associations with symptom improvement,4 even
when taking into account publication bias, source, and timing
of alliance assessment. Other processes, such as treatment ad-
herence,possessalargerandstrongerevidencebasethanothers.5
The field would advance through the adoption of re-
search designs that incorporate more modern analytic
methods2 and track individual patient response to targeted
treatment processes. However, research methods that take into
account the nested nature of treatment and in-session pro-
cesses would provide concrete guidance for the practitioner
in the optimization of effective treatments.
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In Reply I agree with Dr Carney that focusing on residual and
specific symptoms may be another way to improve treatment
outcomes, especially because these residual symptoms are one
of the best predictors of relapse and recurrent depression.
Drs Kazantzis and Hofmann argue that I used1 a simplis-
tic model of depression and that depression is a highly hetero-
geneous disorder. The current model of depression is cer-
tainly simplistic, but it is also the model that has been used in
the past decades in many thousands of studies on the causes,
epidemiology, etiology, and treatments of depression. Fur-
thermore, no alternative model is currently available that can
explain the etiology of depression better or that has been shown
to result in better outcomes of treatments. Dismissing a model
as simplistic is not very useful when no alternative with bet-
ter empirical support is available.
That depression is highly heterogeneous has been recog-
nized by most researchers for several decades. However, de-
spite many attempts to define subtypes of depression, no sub-
type has yet demonstrated a differential response to treatments.2
Network approaches are certainly promising, but no random-
ized trial has yet shown that applying them results in better
outcomes for patients. Many promising innovations have
been announced in the past decades, but unfortunately real im-
provements in outcomes for patients have rarely been seen.
Kazantzis and Hofmann are overly optimistic when they
say that psychological interventions have a high degree of pre-
cision in targeting etiological processes and minimize the com-
plexities of providing evidence for such processes.3 Random-
ized trials can show that a treatment works, but showing how
a treatment works is much more difficult and requires large
numbers of complicated and expensive studies.3 These stud-
ies have not been done even for well-studied treatments such
as cognitive behavioral therapy.4
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They also seem to consider the correlational findings of in-
session processes as strong evidence for how therapies work.
Many hundreds of studies have indeed found associations be-
tweenimprovementinpatientsandcharacteristicsofthetherapy.
However, because these are only uncontrolled and correlational
findings, they cannot be considered as causal evidence.5 If these
processes were as well understood as Kazantzis and Hofmann
assume, one would wonder why the overall low response rates
to treatments have not improved over time and a relatively small
number of patients benefit from them.
As argued in my Viewpoint, substantial progress has been
made in the past decades in the research and development of
treatments for depression. However, it is also time to recog-
nize that these treatments have limitations and that focused
approaches are needed to further reduce the huge disease bur-
den of depression.
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CORRECTION
Numerical Errors and Addition of a Sentence: In the Original Investigation
entitled “Association of Genetic Variants in NUDT15 With Thiopurine-Induced
Myelosuppression in Patients With Inflammatory Bowel Disease,”1 published in
the February 26, 2019, issue of JAMA, there were numerical errors. In the
Results section, Estimated Potential Clinical Effectiveness subsection, second
paragraph, the second sentence should be “For every 10 000 patients geno-
typed, 996 would test positive for a TPMT variant and need to receive an alter-
native therapy to prevent TIM in 81 patients (95% CI, 43-133 patients).” Immedi-
ately after, the following should be added: “Genotyping 10 000 patients for
TPMT would prevent 81 cases of TIM, which is 123 genotyped for every case pre-
vented.” This article was corrected online.
1. Walker GJ, Harrison JW, Heap GA, et al; IBD Pharmacogenetics Study Group.
Association of genetic variants in NUDT15 with thiopurine-induced
myelosuppression in patients with inflammatory bowel disease. JAMA. 2019;321
(8):773-785. doi:10.1001/jama.2019.0709
Error in the Introduction: The Research Letter entitled “Trends in First Gabapen-
tin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017,”1
published in the November 27, 2018, issue of JAMA, included an error in the Intro-
duction that indicated that gabapentin is approved for migraines and generalized
anxiety disorders. The Introduction has been corrected and now indicates that gab-
apentin and pregabalin are approved for epilepsy and neuropathic pain, gabapen-
tin is indicated, but not approved, for migraines, and pregabalin is approved for gen-
eralized anxiety disorders in the United Kingdom. (All other information in the
Introduction was correct and is unchanged.) This article has been corrected online.
1. Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin
prescriptions in primary care in the United Kingdom, 1993-2017. JAMA. 2018;
320(20):2149-2151. doi:10.1001/jama.2018.12358
Data Error: The Original Investigation entitled “Effect of Lanadelumab Com-
pared With Placebo on Prevention of Hereditary Angioedema Attacks: A Random-
ized Clinical Trial,”1 published in the November 27, 2018, issue of JAMA, had a data
error. In the Antidrug Antibodies subsection of the Results, the upper limit of the
range of treatment-emergent antidrug antibodies should have been 1280. This ar-
ticle has been corrected online.
1. Banerji A, Riedl MA, Bernstein JA, et al; HELP Investigators. Effect of
lanadelumab compared with placebo on prevention of hereditary angioedema
attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121. doi:10.1001/
jama.2018.16773
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Letters discussing a recent JAMA article should be submitted within 4
weeks of the article's publication in print. Letters received after 4 weeks
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ing original research should not exceed 600 words of text and 6 refer-
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terial published or submitted for publication. Letters not meeting these
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publication ordinarily will be sent to the authors of the JAMA article, who
will be given the opportunity to reply. Letters will be published at the
discretion of the editors and are subject to abridgement and editing. Fur-
ther instructions can be found at http://jamanetwork.com/journals/
jama/pages/instructions-for-authors. A signed statement for author-
ship criteria and responsibility, financial disclosure, copyright transfer,
and acknowledgment are required before publication. Letters should be
submitted via the JAMA online submission and review system at https://
manuscripts.jama.com. For technical assistance, please contact
jama-letters@jamanetwork.org.
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